Eli Lilly has announced its intention to acquire Centessa Pharmaceuticals in an initial deal valued at $6.3 billion.

Eli Lilly has announced its intention to acquire Centessa Pharmaceuticals for an initial sum of $6.3 billion, expanding its portfolio in the pharmaceutical sector.

An analysis suggests a specific rare-disease specialist company has a superior portfolio and pipeline compared to Centessa Pharmaceuticals.

Eli Lilly announced its intention to acquire Centessa Pharmaceuticals for an initial $6.3 billion, a deal confirmed by recent reports, aiming to bolster its portfolio of sleep medicines and narcolepsy drugs.

A fund has revealed a new $55 million investment in Centessa Pharmaceuticals, coinciding with a 53% stock rally and a change in the company's CEO.